1型早产儿视网膜病变玻璃体腔注射贝伐珠单抗与激光治疗随访至4岁的荧光血管造影表现
单中心随机对照试验纳入21例1型1区早产儿视网膜病变患儿,一眼随机接受0.5mg贝伐珠单抗玻璃体腔注射,对侧眼行常规激光光凝。治疗约4年时荧光血管造影显示,20只贝伐珠单抗治疗眼全部存在周边或后极部异常,而激光治疗眼多数未见这些病变。
要点
- 20只贝伐珠单抗治疗眼在4岁时荧光血管造影均显示周边或后极部异常。
- 19只激光治疗眼中渗漏1只、分流和血管缠结3只、黄斑异常3只。
- 贝伐珠单抗治疗后荧光血管造影异常较激光治疗后更常见。
核心结论
- 荧光血管造影显示,贝伐珠单抗治疗急性期1型早产儿视网膜病变后较激光治疗后更常出现潜在严重且长期的眼部改变。
研究设计与样本
- 单中心随机对照试验,纳入2009年9月1日至2012年3月31日罗马天主教大学新生儿重症监护病房所有患1型1区早产儿视网膜病变的住院婴儿,共21例婴儿42只眼,一眼随机接受0.5mg贝伐珠单抗玻璃体腔注射,对侧眼行常规激光光凝。
主要发现
- 4岁时可随访的20只贝伐珠单抗治疗眼全部显示周边异常(无血管区、血管渗漏、分流、血管分支异常和缠结)或后极部异常(高荧光病灶、黄斑无血管区缺失)。
- 19只激光治疗眼中,渗漏见于1只眼,分流和缠结见于3只眼,黄斑异常见于3只眼。
- 上述病变在大多数激光治疗眼中未观察到。
关键数值与推荐
- 贝伐珠单抗组20只眼全部存在荧光血管造影异常,激光组19只眼中渗漏1只眼、分流和缠结3只眼、黄斑异常3只眼。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare structural outcome at age 4 years of eyes treated with intravitreal injection of bevacizumab with fellow eyes treated with conventional laser photoablation in type 1 retinopathy of prematurity (ROP). DESIGN: Single, randomized, controlled trial. PARTICIPANTS: All inborn babies with type 1 zone 1 ROP at the Neonatal Intensive Care Unit of the Catholic University, Rome, from September 1, 2009, to March 31, 2012. METHODS: In 21 infants (42 eyes), 1 eye was randomized to receive an intravitreal injection of 0.5 mg bevacizumab; the fellow eye underwent conventional laser photoablation. Digital retinal imaging and fluorescein angiography (FA) were performed at an average of 4 years after treatment in follow-up after these studies performed at treatment and 9 months. MAIN OUTCOME MEASURES: Fluorescein angiograms were examined by 2 experts to document retinal and choroidal findings. RESULTS: Among the 20 bevacizumab-treated eyes available at 4 years of age, all showed abnormalities at the periphery (avascular area, vessel leakage, shunts, abnormal vessel branching, and tangles) or the posterior pole (hyperfluorescent lesions, absence of foveal avascular zone). These lesions were not observed in the majority of the lasered eyes. Among the 19 laser-treated eyes, leakage was noted in 1 eye, shunts and tangles were noted in 3 eyes, and macular abnormalities were noted in 3 eyes. CONCLUSIONS: Fluorescein angiography has shown potentially serious and long-term ocular effects that are present more commonly after treatment with bevacizumab for acute-phase ROP than after laser.
引用
- Lepore D, Quinn GE, Molle F, et al. Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings. Ophthalmology. 2017. PMID: 28867130. doi:10.1016/j.ophtha.2017.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。